Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Vaccine maker Novavax is undertaking a new restructuring plan that entails laying off one-fourth of its employees as well as consolidating its facilities and infrastructure 

Biotech company Novavax to layoff 25% of its employees 

Vaccine maker Novavax is undertaking a new restructuring plan that entails laying off one-fourth of its employees as well as consolidating its facilities and infrastructure&nbsp;

Vaccine maker Novavax has announced that the company will layoff 25% of its workforce. The biotech company said that this is done as part of a new restructuring plan. As part of this plan, Novavax will also consolidate its facilities and infrastructure. As per reports, Novavax had around 2,000 employees by the end of 2022.&nbsp;
"Reducing our workforce has been a difficult decision, but we believe it was necessary to better align our infrastructure and scale to the endemic COVID opportunity," said John C Jacobs, President and Chief Executive Officer, Novavax in a statement.&nbsp;
The decision to let go employees has come just days after the World Health Organisation, declared Covid is no longer a global health emergency. Global vaccine makers including Moderna and Pfizer are seeing a drop in demand for Covid-19 vaccines. However, Novavax said that it is focussing on updating its Covid vaccine for the fall vaccine season.&nbsp;
In 2022, Nuvaxovid, Novavax's covid vaccine helped the biotech company to increase its revenue. The company recorded $1.9 billion total revenue, which is 73% more than the revenue recorded in 2021.

Adar Poonawalla, CEO Serum Institute of India announced that the company has started manufacturing the first batch of Covid&nbsp;vaccine&nbsp;Covovax (developed by Novavax) . In a tweet Poonawalla&nbsp;said&nbsp;"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing."Serum&nbsp;has partnered with US bcompany Novavax to conduct bridge trials on the jab and manufacture the vaccine. The govt&nbsp;expects the vaccine to be available&nbsp;from August to December though has not signed any supply contract with SII&nbsp;for the same yet.&nbsp;

Poonawalla says Serum has begun production of Novavax Covid vaccine 

Serum Institute of India begins manufacturing of Novavax&nbsp;Covid-19&nbsp;vaccine at Pune facility.&nbsp;

<ul>
<li>Serum Institute begins production of Novavax covid vaccine</li>
<li>Poonawalla: Excited to witness first batch of Covovax</li>
<li>Poonawalla:'Vaccine has great potential to protect those below 18'</li>
<li>Govt&nbsp;has not signed any supply contract with SII&nbsp;for Novovax&nbsp;yet</li>
<li>Novavax&nbsp;claims to have&nbsp;90.4 % efficacy against Covid-19</li>
</ul>

Adar Poonawalla, CEO Serum Institute of India announced that the company has started manufacturing the first batch of Novovax's&nbsp;Covid&nbsp;vaccine&nbsp;Covovax&nbsp;. In a tweet Poonawalla&nbsp;said&nbsp;"Excited to witness the first batch of Covovax&nbsp;being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing." Serum&nbsp;has partnered with US biotech company Novavax to conduct bridge trials on the jab and manufacture the vaccine. The govt&nbsp;expects the vaccine to be available&nbsp;from August to December though has not signed any supply contract with SII&nbsp;for the same yet.&nbsp;

Serum Institute of India (SII) is expected to begin clinical trials for the Novavax Covid vaccine for children in the month of July, news agency ANI reported. &nbsp;
SII also hopes to introduce Covavax, which is a version of US firm Novavax's Covid-19 vaccine candidate, in the country by September.
Novavax, which has a vaccine manufacturing agreement with SII, has said its Covid vaccine candidate was highly effective with 90.4 per cent efficacy overall and also showed high efficacy against predominantly circulating variants.
Meanwhile, Hyderabad-based Bharat Biotech has already started clinical trials of Covaxin for children 12 to 18 years of age. Bharat Biotech is also conducting clinical trials of its nasal vaccine for children. Zydus Cadila has also begun the trials of vaccine in children aged 12-18.

Serum Institute to start Novavax vaccine trials for children in July: reports

Covid-19: SII&nbsp;to start clinical trials of Novavax shot for children in July
SII&nbsp;to introduce Covavax&nbsp;in India by September this year
Novavax&nbsp;claims to have&nbsp;90.4 % efficacy against Covid-19
Novavax&nbsp;has a vaccine manufacturing agreement with SII&nbsp;in India
Bharat Biotech&nbsp;already started clinical trials of Covaxin for children aged 12-18
Zydus Cadila also begun trials of vaccine in children aged 12-18

Serum Institute of India (SII) is expected to begin clinical trials for the Novavax Covid vaccine for children in the month of July, news agency ANI reported. &nbsp;
SII also hopes to introduce Covavax, which is a version of US firm Novavax's Covid-19 vaccine candidate, in the country by September.
Novavax, which has a vaccine manufacturing agreement with SII, has said its Covid vaccine candidate was highly effective with 90.4 per cent efficacy overall and also showed high efficacy against predominantly circulating variants.
Meanwhile, Hyderabad-based Bharat Biotech has already started clinical trials of Covaxin for children 12 to 18 years of age. Bharat Biotech is also conducting clinical trials of its nasal vaccine for children. Zydus Cadila has also begun the trials of vaccine in children aged 12-18.

The Serum Institute of India hopes to launch Novavax’s Covid-19 vaccine Covovax in India by September if it receives the required regulatory nod by the Centre.

Serum Institute hopes to launch its Novavax Covid-19 vaccine in India by September, says Adar Poonawallaer

The Serum Institute of India hopes to launch Novavax&rsquo;s Covid-19 vaccine &lsquo;Covovax&rsquo; in India by September &nbsp;if it receives the required regulatory nod by the Centre,&nbsp;CEO Adar Poonawalla&nbsp;told CNBC-TV18.&nbsp;
Poonwalla&nbsp;said that the trials for the vaccines are in the advanced stage and are likely to conclude before November. The vaccine manufacturer can apply for licence before the trial concludes based on the global data available for the vaccine.&nbsp;
They are also planning to start a trial of Covovax&nbsp;for children in July
SII&nbsp;entered into an&nbsp;agreement to manufacture Novavax's&nbsp;vaccine named Covovax&nbsp;in September last year.&nbsp;
Novavax in a statement on June 14 stated that it's vaccine candidate showed 100% against moderate and severe Covid-19 infection and 90.4 percent efficacy overall.

Serum Institute hopes to launch its Novavax Covid-19 vaccine in India by September

The Serum Institute of India hopes to launch Novavax&rsquo;s Covid-19 vaccine &lsquo;Covovax&rsquo; in India by September &nbsp;if it receives the required regulatory nod by the Centre,&nbsp;CEO Adar Poonawalla&nbsp;told CNBC-TV18.&nbsp;
Poonwalla&nbsp;said that the trials for the vaccines are in the advanced stage and are likely to conclude before November. The vaccine manufacturer can apply for licence before the trial concludes based on the global data available for the vaccine.&nbsp;
They are also planning to start a trial of Covovax&nbsp;for children in July
SII&nbsp;entered into an&nbsp;agreement to manufacture Novavax's&nbsp;vaccine named Covovax&nbsp;in September last year.&nbsp;
Novavax in a statement on June 14 stated that it's vaccine candidate showed 100% against moderate and severe Covid-19 infection and 90.4 percent efficacy overall.

The Serum Institute of India hopes to launch Novavax&rsquo;s <a href="https://www.editorji.com/covid-19">Covid-19</a> vaccine &lsquo;Covovax&rsquo; in India by September &nbsp;if it receives the required regulatory nod by the Centre,&nbsp;CEO Adar Poonawalla&nbsp;told CNBC-TV18.&nbsp;
Poonwalla&nbsp;said that the trials for the vaccines are in the advanced stage and are likely to conclude before November. The vaccine manufacturer can apply for licence before the trial concludes based on the global data available for the vaccine.&nbsp;
They are also planning to start a trial of Covovax&nbsp;for children in July.&nbsp;SII&nbsp;entered into an&nbsp;agreement to manufacture Novavax's&nbsp;vaccine named Covovax&nbsp;in September last year.&nbsp;
Novavax in a statement on June 14 stated that it's vaccine candidate showed 100% against moderate and severe Covid-19 infection and 90.4 percent efficacy overall.
Also Read | <a href="https://www.editorji.com/story/calf-serum-in-covaxin-govt-and-bharat-biotech-clarify-1623843301997" target="_blank">Calf serum in Covaxin? Govt and Bharat Biotech clarify</a>

US company Novavax says its Covid-19 vaccine demonstrated a final efficacy of 90.4% against mild, moderate, and severe disease caused by original strain in a phase 3 trial in UK.&nbsp;The vaccine maker also said&nbsp;ts shot was highly effective and also protected against variants in a large&nbsp;during&nbsp;late-stage study in the US and Mexico.
The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.
While demand for Covid-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

'Easy to store and transport' Novavax Covid-19 vaccine 90% effective

US company Novavax says its Covid-19 vaccine demonstrated a final efficacy of 90.4% against mild, moderate, and severe disease caused by original strain in a phase 3 trial in UK.&nbsp; The vaccine maker also said&nbsp;ts shot was highly effective and also protected against variants in a large&nbsp;during&nbsp;late-stage study in the US and Mexico. 
The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.
While demand for Covid-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

US company Novavax says its Covid-19 vaccine demonstrated a final efficacy of 90.4% against mild, moderate, and severe disease caused by original strain in a phase 3 trial in UK.&nbsp; The vaccine maker also said&nbsp;ts shot was highly effective and also protected against variants in a large&nbsp;during&nbsp;late-stage study in the US and Mexico. 
The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.
While demand for Covid-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.

There won’t be enough Covid-19 vaccines till 2024: Serum CEO

Adar Poonawalla, the chief executive of Serum Institute of India, has warned there won&rsquo;t be enough vaccines against Covid-19&nbsp;for everyone in the world till the end of 2024.

Serum boss Poonawalla on Covid&nbsp;vaccine production 'There won&rsquo;t be vaccine for&nbsp;everyone&nbsp;till 2024 end' World will need 15 bn doses of vaccine:&nbsp;Poonawalla Serum committed to a billion doses, half for India&nbsp;

Adar Poonawalla, the chief executive of Serum Institute of India, has warned there won&rsquo;t be enough vaccines against Covid-19&nbsp;for everyone in the world till the end of 2024. According to a&nbsp;Financial Times&nbsp;report&nbsp;the CEO&nbsp;of the world&rsquo;s largest vaccine manufacturer has estimated that the world will need around 15 billion doses of the Covid-19 shot if it is a two-dose vaccine.&nbsp;Poonawalla&nbsp;said it&rsquo;s going to take four to five years until everyone gets the vaccine on this planet.&nbsp;The Pune-based pharma firm has partnered with five international pharmaceutical firms, including AstraZeneca and Novavax, to develop a Covid-19 vaccine and committed to producing one billion doses, of which it has pledged half to India.&nbsp;

novavax

Categories